These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 34074622)

  • 1. SARS-COV-2 virus triggers immune antitumor response in a lymphoma patient.
    Rudolphi-Solero T; Rashki M; Fernández-Fernández J; Rivas-Navas D; Ramos-Font C; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2021 May; 42(1):59-60. PubMed ID: 34074622
    [No Abstract]   [Full Text] [Related]  

  • 2. SARS-COV-2 virus triggers immune antitumor response in a lymphoma patient.
    Rudolphi-Solero T; Rashki M; Fernández-Fernández J; Rivas-Navas D; Ramos-Font C; Rodríguez-Fernández A
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(1):59-60. PubMed ID: 35659732
    [No Abstract]   [Full Text] [Related]  

  • 3. T cell responses against SARS-CoV-2 and its Omicron variant in a patient with B cell lymphoma after multiple doses of a COVID-19 mRNA vaccine.
    Atanackovic D; Kreitman RJ; Cohen J; Hardy NM; Omili D; Iraguha T; Burbelo PD; Gebru E; Fan X; Baddley J; Luetkens T; Dahiya S; Rapoport AP
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 infection of intestinal epithelia cells sensed by RIG-I and DHX-15 evokes innate immune response and immune cross-talk.
    Zhang L; Zhang Y; Wang R; Liu X; Zhao J; Tsuda M; Li Y
    Front Cell Infect Microbiol; 2022; 12():1035711. PubMed ID: 36825215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.
    Borges V; Isidro J; Cunha M; Cochicho D; Martins L; Banha L; Figueiredo M; Rebelo L; Trindade MC; Duarte S; Vieira L; Alves MJ; Costa I; Guiomar R; Santos M; Cortê-Real R; Dias A; Póvoas D; Cabo J; Figueiredo C; Manata MJ; Maltez F; Gomes da Silva M; Gomes JP
    mSphere; 2021 Aug; 6(4):e0024421. PubMed ID: 34319130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of post-vaccination SARS-CoV-2 T cell subtypes in patients with different hematologic malignancies and treatments.
    Pfannes R; Pierzchalski A; Maddalon A; Simion A; Zouboulis CC; Behre G; Zenclussen AC; Westphal S; Fest S; Herberth G
    Front Immunol; 2023; 14():1087996. PubMed ID: 37187728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report.
    Nilius-Eliliwi V; Mika T; Baraniskin A; Wünnenberg M; Maslova M; Boy C; Klein-Scory S; Schroers R; Vangala D
    Front Oncol; 2021; 11():706431. PubMed ID: 34336692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.
    Barh D; Tiwari S; Gabriel Rodrigues Gomes L; Weener ME; Alzahrani KJ; Alsharif KF; Aljabali AAA; Tambuwala MM; Lundstrom K; Hassan SS; Serrano-Aroca Á; Takayama K; Ghosh P; Redwan EM; Silva Andrade B; Soares SC; Azevedo V; Uversky VN
    Viruses; 2021 Sep; 13(10):. PubMed ID: 34696358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with a short course of remdesivir in a case of prolonged COVID-19 in a lymphoma patient.
    Kajova M; Kekäläinen E; Anttila VJ; Paajanen J
    Infect Dis (Lond); 2022 Jun; 54(6):455-459. PubMed ID: 35086417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical analysis of prolonged viral clearance time in patients with lymphoma combined with novel coronavirus infection.
    Li Y; Wu C; Fei L; Xu Q; Shao X; Chen B; Sun G
    Front Mol Biosci; 2023; 10():1240175. PubMed ID: 37860581
    [No Abstract]   [Full Text] [Related]  

  • 11. A Case of a Malignant Lymphoma Patient Persistently Infected with SARS-CoV-2 for More than 6 Months.
    Nagasaki Y; Kadowaki M; Nakamura A; Etoh Y; Shimo M; Ishihara S; Arimizu Y; Iwamoto R; Kamamuta S; Iwasaki H
    Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
    Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
    J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural immune response and protection from SARS-CoV-2 reinfection.
    Margiotti K; Fabiani M; Mesoraca A; Giorlandino C
    Acta Virol; 2021; 65(4):333-338. PubMed ID: 34796710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient.
    Hagihara M; Imai Y; Uchida T; Ohara S; Inoue M; Sugi T; Mitamura K
    Intern Med; 2022; 61(14):2215-2219. PubMed ID: 35850990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamical modelling of viral infection and cooperative immune protection in COVID-19 patients.
    Zhou Z; Li D; Zhao Z; Shi S; Wu J; Li J; Zhang J; Gui K; Zhang Y; Ouyang Q; Mei H; Hu Y; Li F
    PLoS Comput Biol; 2023 Sep; 19(9):e1011383. PubMed ID: 37656752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma.
    Suzuki T; Kusumoto S; Kamezaki Y; Hashimoto H; Nishitarumizu N; Nakanishi Y; Kato Y; Kawai A; Matsunaga N; Ebina T; Nakamura T; Marumo Y; Oiwa K; Kinoshita S; Narita T; Ito A; Inagaki A; Ri M; Komatsu H; Aritsu T; Iida S
    Int J Hematol; 2023 Jun; 117(6):900-909. PubMed ID: 36790667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Barcoded Flow Cytometric Assay to Explore the Antibody Responses Against SARS-CoV-2 Spike and Its Variants.
    Vesper N; Ortiz Y; Bartels-Burgahn F; Yang J; de la Rosa K; Tenbusch M; Schulz S; Finzel S; Jäck HM; Eibel H; Voll RE; Reth M
    Front Immunol; 2021; 12():730766. PubMed ID: 34630410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
    Pichler R; Diem G; Hackl H; Koutník J; Mertens LS; D Andrea D; Pradere B; Soria F; Mari A; Laukhtina E; Krajewski W; Teoh JY; Del Guidice F; Moschini M; Thurnher M; Posch W
    Front Immunol; 2023; 14():1202157. PubMed ID: 37520557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19: imbalanced cell-mediated immune response drives to immunopathology.
    Wang J; Li Q; Qiu Y; Lu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2393-2404. PubMed ID: 36069182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immune responses to SARS-CoV-2.
    Dawoodi S; Rizvi SAA; Zaidi AK
    Prog Mol Biol Transl Sci; 2024; 202():127-154. PubMed ID: 38237984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.